InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,348.00
(
0.43%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.76
(
0.40%
)
Bitcoin
61,424.26
(
-0.30%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: ghmm post# 121272

Thursday, 06/09/2011 8:58:19 AM

Thursday, June 09, 2011 8:58:19 AM

Post# of 252412
UTHR

Good point on mono vs addon trial. Makes me realize the risk in FREEDOM-C2 is higher but perhaps you're right and they can file based on FREEDOM-M data alone.
If the drop out were really low this time, they probably have found a way to dose escalate up to 3mg, which is an efficacious dose of Remodulin, but looks like patients did not have sufficient time on that dose (Dr. Rubin's point).
We both have no position but have an acquaintance with PAH.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up